Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral vs IV Topotecan in Relapsed SCLC
NCT00003917Phase 3Completed
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Mar 1999
- Primary completion
- Nov 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of topotecan in small cell lung cancer (SCLC) (2 arms), sponsored by Case Comprehensive Cancer Center. Primary endpoint: Response Rate. Started Mar 1999; status: completed.
02
Drugs
topotecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00003917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003917.